ACE inhibitor pathway (WP554)

Homo sapiens

Open in new tab Open in NDEx Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
The core of this pathway was elucidated over a century ago and involves the conversion of angiotensinogen to angiotensin I (Ang I) by renin, its subsequent conversion to angiotensin II (Ang II) by angiotensin converting enzyme. Ang II activates the angiotensin II receptor type 1 to induce aldosterone synthesis, increasing water and salt resorption and potassium excretion in the kidney and increasing blood pressure. Source: PharmGKB (https://www.pharmgkb.org/pathway/PA2023) Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP554 CPTAC Assay Portal]

Authors

Caroline F. Thorn , Jinwook.seo , Kristina Hanspers , Alex Pico , Thomas Kelder , Martijn Van Iersel , Egon Willighagen , Christine Chichester , Nuno , Denise Slenter , Martina Summer-Kutmon , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Renal Genomics Pathways

Annotations

Pathway Ontology

signaling pathway angiotensin signaling pathway ACE inhibitor drug pathway

Disease Ontology

hypertension

Cell Type Ontology

mesangial cell

Participants
Query Drugst.One

Label Type Compact URI Comment
Bradykinin Metabolite hmdb:HMDB0004246
Ang 1-9 Metabolite kegg.compound:C15851
Ang 1-7 Metabolite chemspider:110354
Angiotensin II Metabolite hmdb:HMDB0001035
ACE inhibitor Metabolite chebi:35457
Deoxycorticosterone Metabolite hmdb:HMDB0000016
Aldosterone Metabolite hmdb:HMDB0000037
Angiotensin I Metabolite pubchem.compound:3081372
Ca2+ Metabolite hmdb:HMDB0000464
Prostacyclin Metabolite pubchem.compound:114805
Ang 1-5 Metabolite kegg.compound:C15852
CYP11B2 GeneProduct ncbigene:1585
ACE2 GeneProduct ncbigene:59272
TGFB1 GeneProduct ncbigene:7040
ACE GeneProduct ncbigene:1636
NOS3 GeneProduct ncbigene:4846
AGTR2 GeneProduct ncbigene:186
NR3C2 GeneProduct ncbigene:4306
KNG1 GeneProduct ncbigene:3827
MAS1 GeneProduct ncbigene:4142
REN GeneProduct ncbigene:5972
BDKRB2 GeneProduct ncbigene:624
CMA1 GeneProduct ncbigene:1215
CTSG GeneProduct ncbigene:1511
BDKRB1 GeneProduct ncbigene:623
AGT GeneProduct ncbigene:183
AGTR1 GeneProduct ncbigene:185
ATP6AP2 GeneProduct ncbigene:10159

References

  1. The regulation of aldosterone synthase expression. Bassett MH, White PC, Rainey WE. Mol Cell Endocrinol. 2004 Mar 31;217(1–2):67–74. PubMed Europe PMC Scholia
  2. Pharmacogenetics of antihypertensive drug responses. Schwartz GL, Turner ST. Am J Pharmacogenomics. 2004;4(3):151–60. PubMed Europe PMC Scholia
  3. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Kidney Int. 2006 Jan;69(1):105–13. PubMed Europe PMC Scholia
  4. The emerging role of ACE2 in physiology and disease. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus ADME, et al. J Pathol. 2007 May;212(1):1–11. PubMed Europe PMC Scholia
  5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR. Clin Ther. 2007 Sep;29(9):1803–24. PubMed Europe PMC Scholia
  6. The (pro)renin receptor: a new addition to the renin-angiotensin system? Batenburg WW, Jan Danser AH. Eur J Pharmacol. 2008 May 13;585(2–3):320–4. PubMed Europe PMC Scholia
  7. Are we poised to target ACE2 for the next generation of antihypertensives? Ferreira AJ, Raizada MK. J Mol Med (Berl). 2008 Jun;86(6):685–90. PubMed Europe PMC Scholia
  8. Mineralocorticoid receptor antagonists and endothelial function. Maron BA, Leopold JA. Curr Opin Investig Drugs. 2008 Sep;9(9):963–9. PubMed Europe PMC Scholia